Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 3, 2001, Pages 1106-1112

  Dominguez, Maria F ^a   Macias, Rocio I R ^a   Izco Basurko, Irantzu ^a   De La Fuente, Antonio ^a   Pascual, Maria J ^a   Criado, Jose M ^a   Monte, Maria J ^a   Yajeya, Javier ^a   Marin, Jose J G ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BAMET R2; BAMET UD2; CISPLATIN; CREATININE; DIAMMINEBISURSODEOXYCHOLATE PLATINUM; DIAMMINECHLOROCHOLYLGLYCINATE PLATINUM; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BONE MARROW TOXICITY; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOSTASIS; DRUG ACCUMULATION; ENTEROHEPATIC CIRCULATION; HEPATOMA CELL; LIVER TUMOR; MALE; NEPHROTOXICITY; NERVE CONDUCTION; NEUROTOXICITY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAPERITONEAL; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; MYOCARDIUM; NEOPLASM TRANSPLANTATION; NEURAL CONDUCTION; ORGANOPLATINUM COMPOUNDS; PLATINUM; RATS; RATS, WISTAR; SCIATIC NERVE; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; URSODEOXYCHOLIC ACID;

EID: 0035016505     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Betebenner DA, Carney PL, Zimmer AM and Kazikiewicz JM (1991) Hepatobiliary delivery of polyaminopolycarboxylate chelates: synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate. Bioconjug Chem 2:117-123.
2. Bignami P, Doci R, Montalto F, Fissi S, Dibartolomeo M and Gennari L (1995) Feasibility of intraportal chemotherapy with fluorouracil and folinic acid immediately after hepatic resection for colorectal metastases. Tumori 81:96-101.
3. Bradner WT, Rose WC and Huttalen JB (1980) Antitumor activity of platinum analogs, in Cisplatin: Current Status and New Developments (Prestayko AW, Crooke ST and Carter SK eds) pp 171-182, Academic Press, New York.
4. Buscher HP, Gerok W, Kollinger M, Kurz G, Muller M, Nolte A and Schneider S (1988) Transport systems for amphipathic compounds in normal and neoplastic hepatocytes. Adv Enzyme Regul 27:173-192.
5. Carlsson G, Gullberg B and Hafstrom L (1983) Estimation of liver-tumor volume using different formulas-An experimental study in rats. J Cancer Res Clin Oncol 105:20-23.
6. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC and Cornblath DR (1994) Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304-311.
7. Criado JJ, Macias RIR, Medarde M, Monte MJ, Serrano MA and Marin JJG (1997) Synthesis and characterization of the new cytostatic complex cis-diammineplatinum(II) chlorocholylglycinate. Cytostatic activity. Bioconjug Chem 8:453-458.
8. Criado JJ, Dominguez MF, Medarde M, Fernandez ER, Macias RIR and Marin JJG (2000) New cis-diamminebis-cholylglycinate(O, O′) Pt(II) and cis-diamminebis-ursodeoxycholate(O, O′) Pt(II) complexes: structural characterization, kinetic studies and biological activity. Bioconjug Chem 11:167-174.
9. De Koning P, Neijt JP, Jennekens FGI and Gispen WH (1987) Evaluation of cis-diamminedichloro platinum(II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 89:81-87.
10. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M and Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795-803.
11. Ho NFH (1987) Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann NY Acad Sci 907:315-329.
12. Hofmann AF (1994) Biliary secretion and excretion. The hepatobiliary component of the enterohepatic circulation of bile acids, in Physiology of the Gastrointestinal Tract (Johnson LR ed) pp 1555-1576, Raven Press, New York.
13. Ishikawa H, Kikkawa F, Tamakoshi K, Matsuzawa K, Kawai M, Suganuma N and Tomoda Y (1996) Distribution of platinum in human gynecologic tissues and lymph nodes after intravenous and intraarterial neoadjuvant chemotherapy. Anticancer Res 16:3849-3853.
14. Kemeny N, Conti JA, Sigurdson E, Cohen A, Seiter K, Lincer R, Niedzwiecki D, Botet J, Chapman D, Costa P and Budd A (1993) A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 71: 1964-1971.
15. Kramer W and Wess G (1996) Bile acid transport systems as pharmaceutical targets. Eur J Clin Invest 26:715-732.
16. Kramer W, Wess G, Schubert G, Bickel M, Hoffmann A, Baringhaus KH, Enhsen A, Glombik H, Mullner S, Neckermann G, et al. (1993) Bile acids as carrier for drugs, in Bile Acids and the Hepatobiliary System. From the Basic Science to the Clinical Practice (Paumgartner G, Stiehl A and Gerok W eds) pp 161-176, Kluwer Academic Publishers, Dordrecht, The Netherlands.
17. Kullak-Ublick GA, Beuers U and Paumgartner G (1996) Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23:1053-1060.
18. Kullak-Ublick GA, Glasa J, Böker C, Oswald M, Grützner U, Hagenbuch B, Stieger B, Meier PJ, Beuers U, Kramer W, et al. (1997) Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113:1295-1305.
19. 2: distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med 14:191-195.
20. Larena MG, Martinez-Diez MC, Monte MJ, Dominguez MF, Pascual MJ and Marin JJG (2001) Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumor activity. J Drug Target, in press.
21. Lipp HP and Bokemeyer C (1999) Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity, in Anticancer Drug Toxicity. Prevention, Management and Clinical Pharmacokinetics (Lipp HP ed) pp 61-81, Marcel Dekker, Tübingen, Germany.
22. Locher PJ and Einhorn LH (1984) Cisplatin. Ann Int Med 100:704-713.
23. Macias RIR, Monte MJ, El-Mir MY, Villanueva GR and Marin JJG (1998) Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. J Lipid Res 39:1792-1798.
24. Macias RIR, El-Mir MY, Monte MJ, Serrano MA, Garcia MJ and Marin JJG (1999) Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). J Control Release 57:161-169.
25. Marchegiano P, Carubbi F, Tiribelli C, Amarri S, Stebel M, Lunazzi GC, Levy D and Bellentani S (1992) Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochem Biophys Res Commun 183:1203-1208.
26. Marin JJG, Macias RIR, Criado JJ, Bueno A, Monte MJ and Serrano MA (1998) DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. Int J Cancer 78:346-352.
27. Martinez-Diez MC, Larena MG, Serrano MA, Macias RIR, Izco-Basurko I and Marin JJG (2000) Relationship between DNA-reactivity and cytostatic activity of two novel bile acid-platinum derivatives, Bamet-UD2 and Bamet-D3. Anticancer Res 20:3315-3321.
28. McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC and Harrap KR (1993) Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxilate complexes in rodents. Br J Cancer 67:996-1000.
29. Meier PJ (1995) Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am J Physiol 32:G801-G812.
30. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T and Kashima K (1999) Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 263:537-542.
31. Monte MJ, Dominguez S, Palomero MF, Macias RIR and Marin JJG (1999) Further evidence for the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. J Hepatol 31:521-528.
32. Sheikh-Hamad D, Timmins K and Jalali Z (1997) Cisplatin-induced renal toxicity: Possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 8:1640-1644.
33. Stanley EF (1981) Sensory and motor nerve conduction velocities and latency of the H reflex during growth of the rat. Exp Neurol 71:497-506.
34. Stephan ZF, Yurachek EC, Sharif R, Wasvary JM, Steele RE and Howes C (1992) Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol 43:1969-1974.
35. Thompson SW, Davis LE, Kornfeld M, Hilgers RD and Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269-1275.
36. Tothill P, Matheson LM, Smyth JF and McKay K (1992) Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry. J Anal Atomic Spectrom 5:619-622.
37. Trauner M and Graziadei IW (1999) Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13:979-995.
38. Unger C (1996) Current concepts of treatment in medical oncology: new anticancer drugs. J Cancer Res Clin Oncol 122:189-198.
39. Von Dippe P and Levy D (1990) Expression of the bile acid transport protein during liver development and in hepatoma cells. J Biol Chem 265:5942-5945.
40. Yang R, Rescorla FJ, Reilly CR, Faught PR, Sanghvi NT, Lumeng L, Franklin TD and Grosfeld JL (1992) A reproducible rat liver cancer model for experimental therapy. Introducing a technique of intrahepatic tumor implantation. J Surg Res 52:193-198.